PARK2 Regulates eIF4B-Driven Lymphomagenesis

Patients with high-risk diffuse large B-cell lymphoma have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP); thus, treatment of this fatal disease remains an area of unmet medical need and requires identification of novel therapeutic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapadia, Bandish B., Roychowdhury, Anirban, Kayastha, Forum, Nanaji, Nahid, Gartenhaus, Ronald B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Cancer Genes and Networks
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339581/
https://www.ncbi.nlm.nih.gov/pubmed/35191952
http://dx.doi.org/10.1158/1541-7786.MCR-21-0729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339581/
https://www.ncbi.nlm.nih.gov/pubmed/35191952
http://dx.doi.org/10.1158/1541-7786.MCR-21-0729

Ejemplares similares